19 completed, 8 active not recruiting, 6 recruiting, 3 not yet recruiting. 41 Phase 1, 14 Phase 2.
Follow Neurofibromatoses: new trials by email Literature Review of Neurofibromatoses trials Research Report on Neurofibromatoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II Trineumin - Neurofibromatosis Type II, NF2 | Phase 1 / Phase 2 | Not yet recruiting | PRG Science & Technology Co., Ltd. | 25 | 2026-07-01 | 2026-01-23 |
| Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas Cabozantinib Oral Tablet, Selumetinib Oral Capsule - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 | Recruiting | Girish Dhall, MD | 30 | 2026-06-09 | 2026-10-02 |
| Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1) | Phase 1 / Phase 2 | Recruiting | AeRang Kim | 45 | 2026-06-01 | 2026-07-27 |
| Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 Imlygic - NF1, Neurofibromatosis | Phase 1 | Recruiting | Johns Hopkins University | 10 | 2026-02-01 | 2026-05-08 |
| Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 Luvometinib Tablets - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 65 | 2025-06-12 | 2025-06-17 |
| PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas PAS-004 Tablets, PAS-004 Capsule - NF1 Mutation, Neurofibroma Plexiform | Phase 1 | Recruiting | Pasithea Therapeutics Corp. | 56 | 2025-05-30 | 2026-10-28 |
| Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs) Kybella - Neurofibromas, Cutaneous, Neurofibromatosis 1 | Phase 1 | Enrolling by invitation | Massachusetts General Hospital | 15 | 2025-04-08 | 2026-04-22 |
| A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia Trametinib, Azacitidine, Fludarabine - Leukemia, Juvenile Myelomonocytic, JMML | Phase 1 / Phase 2 | Recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 58 | 2024-10-11 | 2026-09-04 |
| Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas Deoxycholic Acid, Polidocanol, 1064nm Nd:YAG laser - Neurofibromatosis 1 | Phase 1 | Completed | Massachusetts General Hospital | 13 | 2024-03-01 | 2025-11-21 |
| Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas Kybella, Asclera - Neurofibromatosis 1 | Phase 1 | Completed | Massachusetts General Hospital | 20 | 2022-12-06 | 2025-02-21 |
| Doxycycline in Cutaneous Schwannoma (NF2) Doxycycline Injection [Doxy] - Neurofibromatosis Type 2 | Phase 1 / Phase 2 | Active not recruiting | Massachusetts Eye and Ear Infirmary | 19 | 2022-09-19 | 2026-10-16 |
| DPCP to Treat Cutaneous Neurofibromas Associated With NF1 DPCP - Cutaneous Neurofibroma | Phase 1 | Completed | Nicholas Gulati | 17 | 2022-09-14 | 2024-05-06 |
| NF-1, Nutraceutical Intervention curcumin, high phenolic extra virgin olive oil (HP-EVOO) - Neurofibromatosis 1 | Phase 1 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 23 | 2022-07-06 | 2026-09-23 |
| Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN Selumetinib granule formulation, Selumetinib capsule formulation - Neurofibromatosis Type 1 | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 36 | 2022-01-21 | 2026-08-13 |
| Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas Abemaciclib - Neurofibromatosis 1 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 55 | 2021-11-29 | 2026-11-16 |
| A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 in Patients With Type I Neurofibromatosis TQ-B3234 capsule - Type I Neurofibromatosis | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 120 | 2021-11-01 | 2021-11-04 |
| A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis AL2846 capsules - Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 22 | 2021-09-07 | 2024-03-21 |
| Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas Selumetinib - Neurofibromatosis Type 1 | Phase 1 | Active not recruiting | AstraZeneca | 24 | 2021-07-21 | 2026-08-20 |
| Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas Kybella, 1064nm laser, 755nm Alexandrite Laser - Cutaneous Neurofibroma | Phase 1 | Completed | Massachusetts General Hospital | 34 | 2021-06-02 | 2025-02-21 |
Showing 20 of 41. Sign in to see all of them.
Neurofibromatosis 1 (30) · Neurofibroma, Plexiform (9) · Neurofibromatosis 2 (5) · Neurofibroma (4) · Neurofibrosarcoma (4) · Optic Nerve Glioma (3) · Astrocytoma (2) · Central Nervous System Neoplasms (2) · Angiofibroma (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Castleman Disease (1) · Colorectal Neoplasms (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (41) · Genetic Diseases, Inborn (41) · Heredodegenerative Disorders, Nervous System (41) · Neoplasms by Histologic Type (41) · Neoplasms, Nerve Tissue (41) · Neoplastic Syndromes, Hereditary (41) · Nerve Sheath Neoplasms (41) · Nervous System Diseases (41) · Neurocutaneous Syndromes (41) · Neurodegenerative Diseases (41) · Neoplasms (40) · Neurofibroma (37) · Neuromuscular Diseases (34) · Peripheral Nervous System Diseases (34)
AZD 6244 (9) · Deoxycholic Acid (4) · Cetuximab (2) · Lasers, Solid-State (2) · Magnetic Resonance Spectroscopy (2) · Polidocanol (2) · Sirolimus (2) · Specimen Handling (2) · Acetaminophen (1) · Aminolevulinic Acid (1) · Azacitidine (1) · Bevacizumab (1) · Biopsy (1) · Carboplatin (1) · Curcumin (1)
National Cancer Institute (NCI) (7) · AstraZeneca (5) · Massachusetts General Hospital (5) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (2) · AeRang Kim (1) · Beijing Tiantan Hospital (1) · Children's Oncology Group (1) · FDA Office of Orphan Products Development (1) · Girish Dhall, MD (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · Harry T Whelan, MD (1) · Johns Hopkins University (1) · Kent Robertson (1) · M.D. Anderson Cancer Center (1)
United States (33) · China (6) · Spain (3) · Japan (2) · Russia (2) · Australia (1) · Canada (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · South Korea (1) · United Kingdom (1)
Brigitte C Widemann, M.D. (4) · Richard R Anderson, MD (3) · Jason R Fangusaro (2) · AeRang Kim, MD, PhD (1) · Brigitte C. Widemann, MD (1) · Carlos Romo, MD (1) · Carrie E Bearden, PhD (1) · Clay Hoerig, MD (1) · D. Bradley Welling, MD, PhD (1) · Darren Hargrave, MB Bch (1) · Dusica Babovic-Vuksanovic, MD (1) · Eric Bouffet, MD, MRCP (1) · Girish Dhall, MD (1) · Harry T Whelan, MD (1)
PMID 21764821, PMID 22934754, PMID 26933802, PMID 28029918, PMID 31151904, PMID 32187457, PMID 33470897, PMID 33641042, PMID 35170228, PMID 35410754, PMID 35467749, PMID 37115514, PMID 37311055, PMID 37400844, PMID 38721358, PMID 38869947, PMID 40709016, PMID 41139346, PMID 41389341, PMID 41592259, PMID 42394972, PMID 42540436
UM1CA081457 (2), U01CA081457 (1)